

# Analyst Report

Galia Sotnikova  
Jean-Pierre Loza, PhD



## Quantum Genomics

Euronext Growth Paris: ALQGC [FR0011648971]

10/25/2017

<b>Estimated price:</b>	<b>11.5</b>
Share price (€)*	3.07
Market Cap. (€M)*	33.7
Estimated Market Cap. (€M)	126.3
Number of shares (M)	10.9
YTD High/Low (€)	7.29/3.03
3-month average daily vol.	80.627
Free Float	63.1%
Estimated Net Cash (€M)	6.9

\* as of /10/25/2017

### Quantum genomics published its H-1 2017 financial results and launched the NEW-HOPE study in the United States

Quantum Genomics presented its H1 financial results and additional data on the phase 2a study with its lead drug candidate QGC001, in hypertension. The US phase 2 trial will need to confirm the drug's proof of efficacy in hypertensive patients, which will be decisive for QGC001's future in this indication. In waiting for a clinical timeline on the European market and US market we maintain our target price on Quantum Genomics to €11.51/share.

### NEW-HOPE study in 250 hypertensive overweight patients

QGC001 is a Brain Amino Peptidase Inhibitor (BAPAI), a first-in-class drug candidate addressing severe cardiovascular diseases. The drug has unprecedented mechanisms of action compared to existing antihypertensive drugs, which was implicated in blood pressure regulation. Quantum Genomics believes the unique properties of QGC001 could be a serious alternative for treating patients for whom existing therapies have no or limited effects.

At the end of this August, the Company obtained FDA approval to continue their investigations on QGC001. So, in late September Quantum Genomics launched the NEW-HOPE study, a Phase II clinical trial. The company hope it that will allow to evaluate their molecule on 250 hypertensive patients with a higher cardiovascular risk.

The first patient should be recruited in the Q4 of 2017 and the first results of the NEW-HOPE study are expected in the first half of 2019.



## Financial results and business activity

As of June, 30 2017, operating income amounted to € 4.5 million, compared with € 3.1 in 2016. The increase in expenses reflects the continuation of the clinical studies, the QUID HF study, and the preparation of the NEW HOPE study. Consumption of active substance reached € 0.6 m and external expenses increased by € 0.5 m. Free cash flow (net cash used in operating activities) amounted to € 4 m for the period. After accounting for a net financial expense of € 0.1 million and a research tax credit of € 0.6 million, Quantum Genomics recorded net income of € 4.0 million, compared with a negative € 2.8 million H1 of 2016. As of June 30, 2017, shareholders' equity amounted to € 6.7 million and cash available amounted to € 7.3 million, compared to € 11.2 million at December 31, 2016.

## Valuation

Our previous model considered that phase 2b studies would take place simultaneously in Europe and the US, starting in 2017. Since the company has not yet communicated a clinical timeline on the European study, we now anticipate the study to be delayed by approximately one year, to 2018. We adjusted our target price on Quantum Genomics to €11.51/share.



## Financials

<b>INCOME STATEMENT (€M)</b>						
	2014	2015	2016e	2017e	2018e	2019e
Revenue	0.34	0.17	0.00	0.00	8.71	0.29
EBIT	-2.42	-4.31	-5.61	-6.46	1.54	-3.95
<b>Net Income</b>	<b>-2.21</b>	<b>-3.76</b>	<b>-4.77</b>	<b>-5.49</b>	<b>2.56</b>	<b>-3.77</b>
<b>EARNING PER SHARE (€)</b>						
	2014	2015	2016e	2017e	2018e	2019e
EPS	-0.46	-0.54	-0.54	-0.66	0.31	-0.45
EPS (Diluted)	0.00	-0.50	-0.47	-0.54	0.25	-0.37
<b>CASH FLOW STATEMENT (€M)</b>						
	2014	2015	2016e	2017e	2018e	2019e
<b>Net Income</b>	<b>-2.21</b>	<b>-3.76</b>	<b>-4.77</b>	<b>-5.49</b>	<b>2.56</b>	<b>-3.77</b>
Cash flow from operating activities	-2.21	-3.14	-4.51	-5.03	2.77	-5.06
Cash flow from investment activities	0.00	-0.37	-0.15	-0.15	-0.15	-0.15
Cash Flow from financing activities	0.00	8.84	8.12	-0.02	-0.22	-0.34
<b>Change in cash</b>	<b>-2.21</b>	<b>5.33</b>	<b>3.47</b>	<b>-5.19</b>	<b>2.40</b>	<b>-5.54</b>
<b>BALANCE SHEET (€M)</b>						
<b>ASSETS</b>						
Non current assets	0.62	0.52	0.59	0.67	0.74	0.82
Current assets	4.13	10.02	13.24	8.11	10.57	5.09
<i>Including cash and cash equivalent</i>	3.32	8.65	12.12	6.93	9.33	3.79
<b>Total Assets</b>	<b>4.75</b>	<b>10.54</b>	<b>13.84</b>	<b>8.78</b>	<b>11.32</b>	<b>5.91</b>
<b>LIABILITIES &amp; SHAREHOLDERS EQUITY</b>						
Total Equity	-0.13	8.02	11.32	5.83	8.39	4.62
Total Liabilities	4.88	2.52	2.52	2.96	2.93	1.29
<b>Total Liabilities and shareholders equity</b>	<b>4.75</b>	<b>10.54</b>	<b>13.84</b>	<b>8.78</b>	<b>11.32</b>	<b>5.91</b>

### Disclaimer

This study has been prepared based on general and public information assumed to be complete, exact and pertinent. Although all necessary precautions have been taken to assure that the information used originates from reliable sources, Aurgalys does not guarantee the accuracy or completeness of this report. Neither Aurgalys nor any of its associates may be held liable in any manner whatsoever in the event that any of the documents and other information on which the study has been based proves to be inaccurate and in any way resulting in the possible misrepresentation of the economic and financial position of the Company or any other relevant information. The valuation contained herein has been prepared in accordance with the best assessment of Aurgalys as at the date of preparation of this study and has been based on the information as described above. Neither Aurgalys nor its associates guarantee that the value so obtained will correspond or coincide with the price that could effectively be paid in a transaction or established in a negotiation or any transaction or calculation involving the Company. This document does not constitute an offer or an invitation to buy or subscribe to negotiable or other securities. It may not be used in any manner in support of or in connection with any contract or commitment. This document is being supplied for information purposes only and may not be reproduced or passed on to any third party without the written authorization of Aurgalys. This document has been provided to the Company prior to its distribution. Aurgalys does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. You may call +33(0)1 75 66 20 52 or write to [m.dubourd@aurgalys.com](mailto:m.dubourd@aurgalys.com) to request a copy of this independent research

### About Aurgalys

First company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS n°730782 ACIFTE.

### Aurgalys

1, rue Pierre Fontaine, 91058 Evry Cedex, France

[www.aurgalys.com](http://www.aurgalys.com)

Join our group on [LinkedIn](#)

Follow us on Twitter [@aurgalys](#)